

COVID-19 Vaccine Schedule

COVID-19 vaccines available in Alberta for Spring 2025:

- Moderna Spikevax KP.2 COVID-19 vaccine (6 months of age and older) until June 17, 2025, at which time this product expires.
- Pfizer-BioNTech KP.2 COVID-19 vaccine (12 years of age and older)

TABLE 1: ADDITIONAL KP.2 COVID-19 VACCINE DOSES STARTING APRIL 28, 2025

Eligible groups	KP.2 immunization history	Indicated number of additional doses
Adults 18 years of age and older who reside in continuing care homes and senior supportive living accommodations	Received indicated KP.2 dose(s)	1 dose, at least 3 months from previous KP.2 COVID-19 vaccine dose
Adults 65 years of age and older		
Individuals 6 months of age and older with certain moderate to severe immunocompromising conditions		
First Nations, Métis, and Inuit individuals 6 months of age and older, no matter where they live		

Notes

- **KP.2 immunization history:** See [Table 2](#) and [Table 3](#) on the following pages.
- **Immunocompromised individuals:** Check the list of eligible immunocompromising conditions [here](#).
 - Hematopoietic stem cell transplant (HSCT) recipients and CAR T-cell therapy recipients are recommended to consult with their physician regarding COVID-19 vaccine.

TABLE 2: KP.2 DOSES FOR INDIVIDUALS WHO ARE **NOT IMMUNOCOMPROMISED**

Age Group	COVID-19 Immunization History	Indicated KP.2 COVID-19 vaccine doses	FIRST dose of KP.2 COVID-19 vaccine	SECOND dose of KP.2 COVID-19 vaccine
5 years of age and older	Received 1 or more previous non-KP.2 doses	1	At least <u>3 months</u> from previous non-KP.2 dose	
	Unimmunized	1	As soon as you can	
6 months to 4 years of age	Received 2 or more previous non-KP.2 doses	1	At least <u>3 months</u> from previous non-KP.2 dose	
	Received 1 previous non-KP.2 dose	1	<u>8 weeks</u> from last non-KP.2 dose	
	Unimmunized	2	As soon as you can	<u>8 weeks</u> from FIRST dose

Notes

- **COVID-19 immunization history** refers to any previous dose(s) of mRNA vaccines (original monovalent, bivalent or KP.2 Moderna or Pfizer-BioNTech) and non-mRNA COVID-19 vaccines (AstraZeneca, Janssen, Novavax, and WHO-approved COVID-19 vaccines). If you received a COVID-19 vaccine not approved by Health Canada, please call Health Link (811).

TABLE 3: KP.2 DOSES FOR INDIVIDUALS WHO ARE IMMUNOCOMPROMISED

Immunocompromised individuals should follow the schedule below and receive the appropriate number of KP.2 COVID-19 vaccine to complete a three-dose COVID-19 vaccine series. Regardless of whether they have received one or two non-KP.2 COVID-19 vaccine doses, the previous dose(s) should be counted, and the series should not be restarted.

Age Group	COVID-19 Immunization History	Indicated KP.2 COVID-19 vaccine doses	FIRST dose of KP.2 COVID-19 vaccine	SECOND dose of KP.2 COVID-19 vaccine	THIRD dose of KP.2 COVID-19 vaccine	Additional KP. 2 COVID-19 vaccine dose (on or after April 28, 2025)
6 months of age and older	Received 3 or more previous doses of non-KP.2 vaccine doses	1	At least 3 months from previous non-KP.2 dose			At least 3 months from previous KP.2 dose
	Received 2 previous doses of non-KP.2 vaccine doses	1	8 weeks from last non-KP.2 dose*			
	Received 1 previous dose of non-KP.2 vaccine dose	2	4 weeks from previous non-KP.2 COVID-19 vaccine dose	8 weeks from previous non-KP.2 COVID-19 vaccine dose*		
	Unimmunized	3	As soon as you can	4 weeks after FIRST dose of KP.2 COVID-19 vaccine	8 weeks after SECOND dose of KP.2 COVID-19 vaccine*	

*A 4-week interval may be considered.

Notes

- **COVID-19 immunization history** refers to any previous dose(s) of mRNA vaccines (original monovalent, bivalent or KP.2 Moderna, Pfizer-BioNTech) and non-mRNA COVID-19 vaccines (AstraZeneca, Janssen, Novavax, and WHO-approved COVID-19 vaccines). If you received a COVID-19 vaccine that is not approved by Health Canada, please call Health Link (811).
- Hematopoietic stem cell transplants recipients – pre-transplant and post-transplant while in immunosuppressed state and individuals receiving Chimeric Antigen Receptor T-Cell Therapy (CAR T-cell therapy), please see:
 - [Principles of Immunization in Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients](#)
 - [Child HSCT](#)
 - [Adult HSCT](#)

COVID-19 Vaccine Schedule

TABLE 4: KP.2 DOSES – SPACING POST-INFECTION

NOT IMMUNOCOMPROMISED		
Age group	Vaccine history	Interval between dose and positive COVID-19 test
5 years and older	At least one previous dose	3 months
	Unimmunized	8 weeks
6 months to 4 years	Two or more previous doses	3 months
	One previous dose	8 weeks
	Unimmunized	8 weeks
IMMUNOCOMPROMISED		
Age group	Vaccine history	Interval between dose and positive COVID-19 test
6 months and older	Three or more previous doses	3 months
	One or two previous doses	4 – 8 weeks
	Unimmunized	4 – 8 weeks

Notes

- For individuals with a history of multisystem inflammatory syndrome in children or adults (MIS-C or MIS-A), please consult your primary care provider.